Use of cannabinoids in combination with an anti-psychotic medicament
US9017737B2 · kind B2 · utility
86Cited by
1References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 17, 2008 |
| Grant date | Apr 28, 2015 |
| Priority date | — |
| Expiry date | Mar 7, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.